DaVita HealthCare Partners Inc (DVA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $10.98B
Last updated: Nov 17, 2026 at 11:04 AM ET
DaVita HealthCare Partners Inc (DVA) Earnings: Report Dates and Results
DaVita HealthCare Partners (DVA) is expected to report earnings on Feb 1, 2027. In the quarter ended Sep 30, 2026, DaVita HealthCare Partners reported EPS of $3.82, above the $3.78 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
DVA has an expected report date of Feb 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 23.2% above the $3.40 reported for the quarter ended Dec 31, 2025.
DVA Earnings Call
The latest DVA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, DVA beat 26, missed 12 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $3.58B, up 4.7% from $3.42B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $3.82 | $3.78 | $3.39 - $4.02 | +1.06% | Beat | +52.2% | 7 | 1 up, 0 down | Oct 29, 2026 | $3.58B |
| Jun 30, 2026 | $4.02 | $4.01 | $3.62 - $4.22 | +0.25% | Beat | +36.3% | 6 | 3 up, 2 down | Aug 4, 2026 | $3.55B |
| Mar 31, 2026 | $2.87 | $2.33 | $2.22 - $2.46 | +23.18% | Beat | +43.5% | 6 | 1 up, 0 down | May 5, 2026 | $3.42B |
| Dec 31, 2025 | $3.40 | $3.19 | $3.00 - $3.37 | +6.58% | Beat | +51.8% | 6 | 6 up, 0 down | Feb 2, 2026 | $3.62B |
| Sep 30, 2025 | $2.51 | $3.17 | $3.10 - $3.25 | -20.82% | Miss | -3.1% | 6 | 0 up, 2 down | Oct 29, 2025 | $3.42B |
| Jun 30, 2025 | $2.95 | $2.75 | $2.67 - $2.84 | +7.27% | Beat | +13.9% | 5 | 0 up, 1 down | Aug 5, 2025 | $3.38B |
| Mar 31, 2025 | $2.00 | $2.02 | $1.83 - $2.25 | -0.99% | Miss | -16.0% | 4 | 1 up, 2 down | May 12, 2025 | $3.22B |
| Dec 31, 2024 | $2.24 | $2.13 | $2.07 - $2.31 | +5.16% | Beat | +19.8% | 5 | 3 up, 2 down | Feb 13, 2025 | $3.29B |
| Sep 30, 2024 | $2.59 | $2.72 | $2.61 - $2.85 | -4.78% | Miss | -9.1% | 3 | 0 up, 0 down | Oct 29, 2024 | $3.26B |
| Jun 30, 2024 | $2.59 | $2.63 | $2.42 - $2.75 | -1.52% | Miss | +24.5% | 4 | 1 up, 0 down | Aug 6, 2024 | $3.19B |
| Mar 31, 2024 | $2.38 | $1.92 | $1.86 - $2.07 | +23.96% | Beat | +50.6% | 4 | 1 up, 0 down | May 2, 2024 | $3.07B |
| Dec 31, 2023 | $1.87 | $1.66 | $1.42 - $1.69 | +12.65% | Beat | +216.9% | 3 | 0 up, 0 down | Feb 13, 2024 | $3.15B |
| Sep 30, 2023 | $2.85 | $2.04 | $1.85 - $2.21 | +39.71% | Beat | +96.6% | 3 | 0 up, 0 down | Nov 7, 2023 | $3.12B |
| Jun 30, 2023 | $2.08 | $1.74 | $1.55 - $1.93 | +19.54% | Beat | -9.6% | 3 | 1 up, 0 down | Aug 3, 2023 | $3.00B |
| Mar 31, 2023 | $1.58 | $1.22 | $1.02 - $1.28 | +29.51% | Beat | -1.9% | 4 | 0 up, 0 down | May 8, 2023 | $2.87B |
| Dec 31, 2022 | $0.59 | $0.91 | $0.73 - $1.00 | -35.16% | Miss | -70.8% | 4 | 0 up, 0 down | Feb 22, 2023 | $2.92B |
| Sep 30, 2022 | $1.45 | $1.76 | $1.60 - $1.98 | -17.61% | Miss | -38.6% | 6 | 1 up, 0 down | Oct 28, 2022 | $2.95B |
| Jun 30, 2022 | $2.30 | $2.08 | $1.98 - $2.17 | +10.58% | Beat | -12.9% | 5 | 0 up, 0 down | Aug 1, 2022 | $2.93B |
| Mar 31, 2022 | $1.61 | $1.87 | $1.77 - $1.96 | -13.90% | Miss | -23.0% | 5 | 0 up, 0 down | May 5, 2022 | $2.82B |
| Dec 31, 2021 | $2.02 | $1.80 | $1.66 - $1.93 | +12.22% | Beat | +21.0% | 7 | 0 up, 0 down | Feb 10, 2022 | $2.94B |
| Sep 30, 2021 | $2.36 | $2.26 | $2.18 - $2.37 | +4.42% | Beat | +31.1% | 6 | N/A | Oct 28, 2021 | $2.94B |
| Jun 30, 2021 | $2.64 | $2.17 | $2.11 - $2.25 | +21.66% | Beat | +35.4% | 7 | N/A | Aug 3, 2021 | $2.92B |
| Mar 31, 2021 | $2.09 | $1.79 | $1.65 - $1.95 | +16.76% | Beat | +14.2% | 7 | N/A | Apr 29, 2021 | $2.82B |
| Dec 31, 2020 | $1.67 | $1.87 | $1.61 - $1.96 | -10.70% | Miss | -10.2% | 10 | N/A | Feb 11, 2021 | $5.66B |
| Sep 30, 2020 | $1.80 | $1.44 | $1.17 - $1.63 | +25.00% | Beat | +17.6% | 11 | N/A | Oct 29, 2020 | $2.92B |
| Jun 30, 2020 | $1.95 | $1.30 | $1.19 - $1.37 | +50.00% | Beat | +59.8% | 10 | N/A | Jul 30, 2020 | $121.78M |
| Mar 31, 2020 | $1.83 | $1.47 | $1.38 - $1.58 | +24.49% | Beat | +101.1% | 10 | N/A | May 5, 2020 | $2.84B |
| Dec 31, 2019 | $1.86 | $1.66 | $1.42 - $1.75 | +12.05% | Beat | +106.7% | 12 | N/A | Feb 10, 2020 | $2.90B |
| Sep 30, 2019 | $1.53 | $1.24 | $1.12 - $1.38 | +23.39% | Beat | +173.2% | 12 | N/A | Nov 5, 2019 | $2.90B |
| Jun 30, 2019 | $1.22 | $1.11 | $0.98 - $1.46 | +9.91% | Beat | +16.2% | 12 | N/A | Aug 1, 2019 | $2.84B |
| Mar 31, 2019 | $0.91 | $0.93 | $0.89 - $1.02 | -2.15% | Miss | -13.3% | 11 | N/A | May 7, 2019 | $2.74B |
| Dec 31, 2018 | $0.90 | $0.90 | $0.77 - $0.99 | 0.00% | In line | -2.2% | 11 | N/A | Feb 13, 2019 | $2.82B |
| Sep 30, 2018 | $0.56 | $0.88 | $0.79 - $0.92 | -36.36% | Miss | -30.9% | 8 | N/A | Nov 7, 2018 | $2.85B |
| Jun 30, 2018 | $1.05 | $0.97 | $0.86 - $1.05 | +8.25% | Beat | +14.1% | 9 | N/A | Aug 1, 2018 | $2.89B |
| Mar 31, 2018 | $1.05 | $0.92 | $0.88 - $0.95 | +14.13% | Beat | +32.9% | 6 | N/A | May 3, 2018 | $2.85B |
| Dec 31, 2017 | $0.92 | $0.92 | $0.89 - $1.10 | 0.00% | In line | -6.1% | 9 | N/A | Feb 13, 2018 | $2.93B |
| Sep 30, 2017 | $0.81 | $0.94 | $0.88 - $0.99 | -13.83% | Miss | -14.7% | 10 | N/A | Nov 7, 2017 | $2.88B |
| Jun 30, 2017 | $0.92 | $0.90 | $0.84 - $1.04 | +2.22% | Beat | -8.9% | 10 | N/A | Aug 1, 2017 | $2.81B |
| Mar 31, 2017 | $0.79 | $0.81 | N/A | -2.47% | Miss | -14.1% | N/A | N/A | May 2, 2017 | $2.74B |
| Dec 31, 2016 | $0.98 | $0.91 | N/A | +7.69% | Beat | -3.0% | N/A | N/A | Feb 16, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $10.86, up 10.8% from the year before. It was $3.86 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $10.86 | +10.8% |
| Dec 31, 2024 | $9.80 | +16.9% |
| Dec 31, 2023 | $8.38 | +40.8% |
| Dec 31, 2022 | $5.95 | -34.7% |
| Dec 31, 2021 | $9.11 | +25.7% |
| Dec 31, 2020 | $7.25 | +31.3% |
| Dec 31, 2019 | $5.52 | +55.1% |
| Dec 31, 2018 | $3.56 | +3.5% |
| Dec 31, 2017 | $3.44 | -10.9% |
| Dec 31, 2016 | $3.86 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,800 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,834 | 10 | |
| 2026Q2 | Jun 30, 2026 | 4,725 | 10 | |
| 2026Q1 | Mar 31, 2026 | 4,445 | 10 | |
| 2025Q4 | Dec 31, 2025 | 5,592 | 10 | |
| 2025Q3 | Sep 30, 2025 | 5,123 | 10 | |
| 2025Q2 | Jun 30, 2025 | 6,095 | 11 | |
| 2025Q1 | Mar 31, 2025 | 4,632 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,962 | 8 |
2026Q3 Earnings Call
Opening remarks
Nic Eliason Group Vice President, Investor Relations Thank you, and welcome to our third quarter conference call. We appreciate your continued interest in our company. I'm Nic Eliason, Group Vice President of Investor Relations. Joining me today are Javier Rodriguez, our CEO, and Joel Ackerman, our CFO. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our third quarter earnings press release and our SEC filings, including our most recent annual report on Form 10-K, all subsequent quarterly reports on Form 10-Q, and other subsequent filings that we make with the SEC. Our forward-looking statements are based on information currently available to us, and we do not intend or undertake any duty to update these statements, except as may be required by law. Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures. A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our earnings press release furnished to the SEC and available on our website. I will now turn the call over to Javier Rodriguez.
Javier Rodriguez CEO Thank you, Nic. Good afternoon, everyone, and thank you for joining the call today. Once again, our teammates have delivered excellent care for our patients and solid results for our shareholders. We're seeing meaningful progress across our clinical strategy, with investments in innovation translating into better patient outcomes and stronger business performance. Our maturing Integrated Kidney Care business is a prime example, as it continues to deliver clinical performance for our patients while starting to demonstrate its economic potential. In the same spirit, our rollout of expanded HD dialyzers marks an exciting new chapter in how we're advancing kidney care. Today, I'll share more on these priorities, review our third quarter financial performance, provide our outlook for the remainder of the year, and briefly discuss policy. But first, as always, let's begin with our clinical highlight. Today, I will highlight our advancements in fluid management. We're often asked about the clinical drivers behind our recent mortality improvements, and fluid overload is one of those critical areas we target. Because kidney failure impairs the body's ability to shed fluid, managing fluid intake between treatments and safely removing excess fluid during dialysis requires constant vigilance from both patients and care teams. Left unmanaged, excess fluid places strain on the cardiovascular and pulmonary systems, contributing to high blood pressure, heart failure, and respiratory difficulties.
Frequently Asked Questions About DVA
When is DaVita HealthCare Partners's next earnings date?
DaVita HealthCare Partners's next earnings report is expected for Feb 1, 2027.
Did DVA beat earnings estimates last quarter?
Yes. DaVita HealthCare Partners reported EPS of $3.82 for the quarter ended Sep 30, 2026, above the $3.78 estimate, a 1.06% surprise.
What EPS do analysts expect from DVA next quarter?
The consensus EPS estimate for DaVita HealthCare Partners for the quarter ending Dec 31, 2026 is $4.19 from 8 analysts, with estimates from $3.92 to $4.56.
How often does DVA beat earnings estimates?
DaVita HealthCare Partners beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +2.71%.
DVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors